Foresite Capital Management IV’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Foresite Capital Management IV’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-156,355	Closed	-$5.32M	–	18
2020 Q1	$5.32M	Buy	+156,355	New	+$7.15M	6.56%	5
2019 Q4	–	Sell	-425,794	Closed	-$17.8M	–	21
2019 Q3	$17.8M	Sell	425,794 -3,896	-0.9%	-$165K	5.74%	7
2019 Q2	$18.8M	Sell	429,690 -88,870	-17%	-$5.01M	5.32%	6
2019 Q1	$26.7M	Sell	518,560 -337,340	-39%	-$14.6M	9.59%	4
2018 Q4	$31.7M	Buy	855,900 +4,700	+0.6%	+$169K	14.53%	1
2018 Q3	$32M	Hold	851,200	–	–	10.48%	3
2018 Q2	$33.6M	Hold	851,200	–	–	11.47%	2
2018 Q1	$21.9M	Buy	851,200 +637,765	+299%	+$19.1M	9.09%	4
2017 Q4	$5.76M	Buy	+213,435	New	+$5.88M	4.04%	9

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Foresite Capital Management IV's BHVN Position: Q2 2020 in Review

Foresite Capital Management IV sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2020, closing a stake of 156,355 shares — an estimated $5.32M sold.

Foresite Capital Management IV first reported a position in BHVN in Q4 2017 and held it in 9 quarters. The position peaked at $33.6M in Q2 2018. 226 funds tracked by Wall St. Rank hold BHVN as of Q2 2020.

Foresite Capital Management IV reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2020 after selling out during the quarter.
Foresite Capital Management IV sold 156,355 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2020, an estimated $5.32M.
Foresite Capital Management IV first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 9 quarters.
Foresite Capital Management IV's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $33.6M in Q2 2018.
226 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2020.

Based on Foresite Capital Management IV's 13F filing for Q2 2020, filed 13 Aug 2020.